Literature DB >> 1634526

Eosinophil-derived neurotoxin and human liver ribonuclease. Identity of structure and linkage of neurotoxicity to nuclease activity.

S Sorrentino1, D G Glitz, K J Hamann, D A Loegering, J L Checkel, G J Gleich.   

Abstract

Eosinophil-derived neurotoxin (EDN) and human liver RNase were found to be indistinguishable from each other but distinct from the pancreatic ribonucleases in their nucleolytic activity on polynucleotides or small defined substrates. Antibodies to EDN and liver RNase showed identical cross-reactivities in assays of nuclease inhibition and in a radioimmunoassay. In each instance, EDN and liver RNase were easily distinguished from bovine or human pancreatic RNase. When injected intrathecally into rabbits, 5-10 micrograms of EDN or liver RNase each was neurotoxic as judged by induction of the Gordon phenomenon. Human pancreatic RNase was less neurotoxic, and up to 20-fold higher levels of bovine pancreatic RNase showed no effect. Treatment of EDN, liver RNase, and eosinophil cationic protein with iodoacetic acid at pH 5.5 resulted in inactivation of their RNase activity and also destroyed their neurotoxicity. EDN conformation was not greatly affected by iodoacetate treatment since interaction of the modified protein with antibodies was only slightly altered. We conclude that RNase activity is necessary but not sufficient to induce neurotoxic action.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1634526

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Diversity among the primate eosinophil-derived neurotoxin genes: a specific C-terminal sequence is necessary for enhanced ribonuclease activity.

Authors:  H F Rosenberg; K D Dyer
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

2.  Two highly homologous ribonuclease genes expressed in mouse eosinophils identify a larger subgroup of the mammalian ribonuclease superfamily.

Authors:  K A Larson; E V Olson; B J Madden; G J Gleich; N A Lee; J J Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  The activity on double-stranded RNA of aggregates of ribonuclease A higher than dimers increases as a function of the size of the aggregates.

Authors:  M Libonati; M Bertoldi; S Sorrentino
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

Review 4.  Eosinophils, ribonucleases and host defense: solving the puzzle.

Authors:  H F Rosenberg; J B Domachowske
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

5.  Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation.

Authors:  Esther Carreras; Ester Boix; Susanna Navarro; Helene F Rosenberg; Claudi M Cuchillo; M Victòria Nogués
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

6.  Ribonuclease A variants with potent cytotoxic activity.

Authors:  P A Leland; L W Schultz; B M Kim; R T Raines
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 7.  Eosinophil granule proteins: form and function.

Authors:  K Ravi Acharya; Steven J Ackerman
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

Review 8.  Eosinophil-derived neurotoxin / RNase 2: connecting the past, the present and the future.

Authors:  H F Rosenberg
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

9.  Eosinophil ribonucleases and their cutaneous lesion-forming activity.

Authors:  Douglas A Plager; Mark D P Davis; Amy G Andrews; Michael J Coenen; Terry J George; Gerald J Gleich; Kristin M Leiferman
Journal:  J Immunol       Date:  2009-08-28       Impact factor: 5.422

10.  Influence of naturally-occurring 5'-pyrophosphate-linked substituents on the binding of adenylic inhibitors to ribonuclease a: an X-ray crystallographic study.

Authors:  Daniel E Holloway; Gayatri B Chavali; Demetres D Leonidas; Matthew D Baker; K Ravi Acharya
Journal:  Biopolymers       Date:  2009-12       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.